Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 11/20 | 0.61 |
| ▸ | ATF4 | P18848 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5671599 | 0.86 | MCHR1 (0.53) | MCHR1ATF4CHRM1CHRM3CYP1A2 | |
| SCHEMBL5670333 | 0.86 | MCHR1 (0.51) | MCHR1ATF4CHRM1CHRM3CYP1A2 | |
| SCHEMBL5122821 | 0.85 | LMNA (0.58) | ATF4CYP1A2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL4033699 | 0.84 | ATF4 (0.81) | ATF4HPGDHTTRAB9A | |
| SCHEMBL5123998 | 0.84 | POLB (0.62) | ATF4CYP1A2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL19692630 | 0.84 | ATF4 (0.59) | ATF4CYP1A2CYP3A4CYP2C19SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL19692584 | 0.83 | ATF4 (0.79) | ATF4HPGDHTTRAB9A | |
| SCHEMBL5116283 | 0.83 | SMN1; SMN2 (0.54) | MCHR1ATF4CYP1A2CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL19692616 | 0.82 | ATF4 (0.58) | ATF4CYP1A2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL5122790 | 0.82 | CYP1A2 (0.56) | MCHR1ATF4CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300232-A1 | N-Piperidine Derivatives as Ccr3 Modulators | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | claimed |
| CN-1934099-A | N-piperidine derivates as CCR3 modulators | ASTRAZENECA AB (SE) | 2007-03-21 | — | — | CN | claimed |
| US-20080300232-A1 | N-Piperidine Derivatives as Ccr3 Modulators | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | disclosed |
| CN-1934099-A | N-piperidine derivates as CCR3 modulators | ASTRAZENECA AB (SE) | 2007-03-21 | — | — | CN | disclosed |
| EP-1730136-A1 | N-PIPERIDINE DERIVATES AS CCR3 MODULATORS | AstraZeneca AB (SE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005090330-A1 | N-PIPERIDINE DERIVATES AS CCR3 MODULATORS | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300232-A1 | N-Piperidine Derivatives as Ccr3 Modulators | CCR3, CCR1, CCR4 | MCHR1 892/4885ATF4 980/4885CHRM1 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.